

# Johan Filip Vansteenkiste

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5612252/johan-filip-vansteenkiste-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266  
papers

36,573  
citations

73  
h-index

190  
g-index

288  
ext. papers

44,429  
ext. citations

5.7  
avg, IF

6.64  
L-index

#	Paper	IF	Citations
266	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101308	2.2	42
265	Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.. <i>Lung Cancer</i> , <b>2022</b> , 166, 242-249	5.9	
264	ANTIangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 112-125	7.5	0
263	Value of [Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.. <i>EJNMMI Research</i> , <b>2022</b> , 12, 28	3.6	0
262	A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.. <i>Acta Oncologica</i> , <b>2022</b> , 1-4	3.2	1
261	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. <i>Lung Cancer</i> , <b>2021</b> , 154, 92-98	5.9	2
260	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 860-867	8.9	118
259	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. <i>Acta Clinica Belgica</i> , <b>2021</b> , 76, 224-231	1.8	1
258	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 270-280	8.9	22
257	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1369-1378	8.9	5
256	Abemaciclib in Combination With Pembrolizumab for Stage IV -Mutant or Squamous NSCLC: A Phase 1b Study. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100234	1.4	4
255	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1472-1483	8.9	10
254	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 709-740	8.9	77
253	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. <i>Cancer Cell</i> , <b>2020</b> , 37, 21-36.e13	24.3	93
252	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 392-403	8.9	29
251	Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial. <i>European Journal of Cancer</i> , <b>2020</b> , 125, 94-103	7.5	5
250	Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 41-50	59.2	771

249	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , <b>2020</b> , 147, 137-142	5.9	13
248	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 944-957	59.2	214
247	A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 457-467	4.3	11
246	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. <i>Pathology and Oncology Research</i> , <b>2020</b> , 26, 1221-1228	2.6	2
245	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 288-293	8.9	203
244	Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 138-143	8.9	18
243	A Th1/IFN $\gamma$ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1725-1735	12.9	6
242	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6644-6652	12.9	53
241	A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 137, 136-143	5.9	5
240	Current status of immune checkpoint inhibition in early-stage NSCLC. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1244-1253	12.5	43
239	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , <b>2019</b> , 131, 95-103	5.9	22
238	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , <b>2019</b> , 39, 1403-1409	2.3	5
237	Capmatinib for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 659-671	3.5	34
236	ASTRIS: a global real-world study of osimertinib in >3000 patients with T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 3003-3014	3.6	27
235	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 2109-2119	8.9	96
234	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 28-35	7.5	6
233	Three-year overall survival update from the PACIFIC trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8526-8526	12.5	20
232	Lung cancer: diagnosis and staging <b>2019</b> , 453-462		

231	Immunotherapy in patients with early stage resectable nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2019</b> , 31, 13-17	4.2	21
230	Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography-computed tomography?. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2018</b> , 54, 134-140	3	15
229	Immunotherapy in lung cancer. <i>ESMO Open</i> , <b>2018</b> , 3, e000311	6	2
228	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 413-425	8.9	48
227	Will liquid biopsies become our fluid transition to personalized immunotherapy?. <i>Annals of Oncology</i> , <b>2018</b> , 29, 11-13	10.3	1
226	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 331-339	4.9	13
225	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 521-536	21.7	315
224	Immunotherapy and Lung Cancer <b>2018</b> , 501-511.e3		2
223	Phenotype molding of stromal cells in the lung tumor microenvironment. <i>Nature Medicine</i> , <b>2018</b> , 24, 1277-1289	50.5	607
222	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue. <i>Radiation Oncology</i> , <b>2018</b> , 13, 131	4.2	5
221	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1701-1709	10.3	11
220	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8510-8510	2.2	15
219	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 113-125	59.2	2098
218	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3101-3109	2.2	146
217	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018783118	2.2	284
216	Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer. <i>ESMO Open</i> , <b>2018</b> , 3, e000429	6	1
215	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1468-1479	21.7	237
214	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2342-2350	59.2	1336

213	Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2877-2888	3.8	14
212	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 17588359187728104	5.4	11
211	A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer. <i>Respiration</i> , <b>2018</b> , 96, 275-282	3.7	21
210	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 1844-1853	27.4	211
209	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1109-1121	8.9	193
208	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. <i>Nature</i> , <b>2017</b> , 546, 168-172	50.4	136
207	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 781-789	5.4	11
206	Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2502-2502	2.2	21
205	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9036-9036	2.2	10
204	A 65-Year-Old Patient with Superior Vena Cava Syndrome and Bone Metastases. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 2033-2035	8.9	
203	Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1538-49	8.9	12
202	Postoperative radiotherapy for lung cancer: Is it worth the controversy?. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 51, 10-18	14.4	10
201	The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database. <i>Lung Cancer</i> , <b>2016</b> , 102, 96-100	5.9	1
200	Characteristics and outcome of unplanned hospital admissions in patients with lung cancer: a longitudinal tertiary center study. Towards a strategy to reduce the burden. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2827-35	3.9	4
199	Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 120, 273-8	5.3	27
198	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1204-1223	8.9	333
197	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 953-62	2.2	254
196	Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin $\geq$ 10 g/dL. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 122-135.e6	3.5	5

195	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 300-11	8.9	218
194	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 85-93	8.9	17
193	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 452-463	21.7	318
192	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , <b>2016</b> , 21, 292-300	5.7	28
191	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 666-680	8.9	116
190	The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 284-6	8.9	7
189	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 651-665	8.9	148
188	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , <b>2016</b> , 387, 1837-46 <sup>0</sup>		1731
187	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 639-650	8.9	122
186	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 39-51	8.9	1888
185	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9028-9028	2.2	15
184	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9032-9032	2.2	14
183	Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9064-9064	2.2	12
182	Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14098-e14098	2.2	4
181	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). <i>PLoS ONE</i> , <b>2016</b> , 11, e0147599	3.7	17
180	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 3068-83	3.3	17
179	Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8557-8557	2.2	
178	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e450-8	7.1	22

177	Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 516-23	8.9	40
176	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 822-835	21.7	289
175	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1940-1953	8.9	13
174	Lung cancer at the intensive care unit: The era of targeted therapy. <i>Lung Cancer</i> , <b>2015</b> , 89, 218-21	5.9	19
173	Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). <i>Annals of Oncology</i> , <b>2015</b> , 26, 1734-40	10.3	46
172	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1573-88	10.3	225
171	Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1751-61	13.6	29
170	DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature. <i>Thorax</i> , <b>2015</b> , 70, 1113-22	7.3	27
169	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1319-1327	8.9	112
168	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1458-67	8.9	43
167	Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 57	3	3
166	Immunotherapy for non-small-cell lung cancer: the past 10 years. <i>Future Oncology</i> , <b>2015</b> , 11, 2681-2695	3.6	6
165	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1675-84	8.9	358
164	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. <i>Lung Cancer</i> , <b>2015</b> , 88, 63-9	5.9	60
163	Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging. <i>Radiology</i> , <b>2015</b> , 274, 576-84	20.5	35
162	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 730-8	12.9	215
161	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 7506-7506	2.2	7
160	Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8010-8010	2.2	67

159	Characterisation of solitary pulmonary lesions combining visual perfusion and quantitative diffusion MR imaging. <i>European Radiology</i> , <b>2014</b> , 24, 531-41	8	25
158	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 83, 211-8	5.9	53
157	Ceritinib in ALK-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1189-97	5.9	1119
156	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1462-74	10.3	268
155	Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. <i>Respiration</i> , <b>2014</b> , 87, 204-10	3.7	4
154	Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 110, 3-8	5.3	93
153	Immunotherapy for lung cancer: ongoing clinical trials. <i>Future Oncology</i> , <b>2014</b> , 10, 91-105	3.6	21
152	Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 1925-39	3.6	9
151	A rare central thoracic tumor. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 897-9	8.9	1
150	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. <i>Translational Respiratory Medicine</i> , <b>2014</b> , 2, 9		12
149	Corrigendum to Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis [Radiother Oncol 110 (2014) 38]. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 113, 300-301	5.3	10
148	Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 365-76	5.4	7
147	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1475-84	10.3	174
146	The European initiative for quality management in lung cancer care. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 1254-77	13.6	28
145	Vaccination therapy for non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 165-70	4.2	31
144	Early stage lung cancer: progress in the last 40 years [corrected]. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1434-42	8.9	11
143	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1681-1690	10.3	208
142	Suitability of small bronchoscopic tumour specimens for lung cancer genotyping. <i>Respiration</i> , <b>2014</b> , 88, 371-7	3.7	10



141	Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1675-84	8.9	19
140	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8003-8003	2.2	18
139	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8017-8017	2.7	27
138	Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8078-8078	2.2	6
137	START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS7608-TPS7608	2.2	2
136	Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6, 574-7	2.6	2
135	Targeting the immune system for management of NSCLC: the revival?. <i>Current Respiratory Care Reports</i> , <b>2013</b> , 2, 22-39		1
134	Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 987-92	3.9	7
133	Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2396-403	2.2	241
132	Chemotherapy-induced anemia: the story of darbepoetin alfa. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 325-37	2.5	6
131	Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 175-82	4.3	49
130	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 38-47	21.7	536
129	Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1405-10	3.2	38
128	Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. <i>Acta Oncologica</i> , <b>2013</b> , 52, 18-29	3.2	61
127	Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2388-95	2.2	251
126	An unusual cause of Dysphagia in a 76-year-old heavy smoker. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1339-40		40
125	Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8010-8010	2.2	24
124	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8063-8063	2.2	7

123	Positron Emission Tomography Imaging <b>2012</b> , 122-132		
122	Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3084-92	2.2	214
121	Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. <i>Lung Cancer</i> , <b>2012</b> , 76, 478-85	5.9	33
120	Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of . <i>Medical Oncology</i> , <b>2012</b> , 29, 2291-9	3.7	13
119	Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 172-8	2.2	157
118	Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 529-39	3.5	5
117	A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemo-naïve patients with advanced non-small cell lung cancer. <i>Oncology</i> , <b>2012</b> , 82, 25-9	3.6	12
116	Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1383-90	3.5	3
115	Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience. <i>Radiology</i> , <b>2012</b> , 263, 884-92	20.5	71
114	Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1291-5	8.9	23
113	MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7013-7013	2.2	2
112	Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7503-7503	2.2	20
111	Patient (Pt) and caregiver (Cg) perspectives in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4-4	2.2	1
110	Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. <i>Lung Cancer</i> , <b>2011</b> , 73, 11-7	5.9	47
109	Reply to On Plain Language and Going Astray <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 650-651	8.9	
108	Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 2120-9	8.9	28
107	A practical guide to measure "all" malignant pleural mesothelioma tumors by modified RECIST criteria?. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 2143-4; author reply 2144-5	8.9	5
106	Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1067-74	2.2	234

105	Erythropoiesis-stimulating agents in cancer patients: reflections on safety. <i>Expert Review of Clinical Pharmacology</i> , <b>2011</b> , 4, 467-76	3.8	5
104	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 244-85	8.9	3178
103	Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 64-70	8.9	198
102	Lung cancer: progress in diagnosis, staging and therapy. <i>Respirology</i> , <b>2010</b> , 15, 44-50	3.6	73
101	Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 7, vii189-95	10.3	19
100	Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer. <i>Respiration</i> , <b>2010</b> , 79, 97-104	3.7	4
99	A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2010</b> , 68, 420-6	5.9	50
98	Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 2245-52	27.4	403
97	The seventh tumor, node, metastasis staging system and lung cancer treatment choices: a matter of would, could, and should. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1724-5	8.9	4
96	Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2838-47	2.2	113
95	Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2009</b> , 36, 433-9	3	73
94	Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 822-8	8.9	49
93	Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. <i>Expert Opinion on Biological Therapy</i> , <b>2009</b> , 9, 221-30	5.4	9
92	Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. <i>BMC Cancer</i> , <b>2009</b> , 9, 311	4.8	19
91	The multidisciplinary of stage III non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2009</b> , 45 Suppl 1, 92-105	7.5	8
90	Unexpected slight fluorodeoxyglucose-uptake on positron emission tomography in a pulmonary hamartoma. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 107-8	8.9	6
89	Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 62-8	8.9	19
88	Esophageal ultrasound-controlled fine needle aspiration for staging of mediastinal lymph nodes in patients with resectable lung cancer: do we always see the reality?. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 1043-5	8.9	4

87	Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 1221-5	8.9	4
86	PET Imaging <b>2008</b> , 69-78		
85	Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data?. <i>Lung Cancer</i> , <b>2008</b> , 62, 126-38	5.9	13
84	Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3543-51	2.2	2607
83	Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1611-8	2.2	153
82	Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2342-9	2.2	85
81	Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1128-34	2.2	97
80	Survival after resection of synchronous bilateral lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2008</b> , 34, 1215-22	3	73
79	Second-line treatment of advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 430-40	8.9	52
78	An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 174-6	8.9	2
77	Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 662-3	8.9	0
76	Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 894-901	8.9	19
75	Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 483-8	4.3	138
74	Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1545-52	2.2	777
73	Staging of lung cancer. <i>Radiologic Clinics of North America</i> , <b>2007</b> , 45, 609-25, v	2.3	13
72	B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S334-S335	8.9	4
71	P3-079: Prospective evaluation of first-line tyrosine kinase inhibition with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene (FIETL study). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S712	8.9	2
70	M17-05: MAGE-A3 vaccine. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S202	8.9	

69	B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S349-S350	8.9	3
68	C6-01: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemo-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S375	8.9	5
67	Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. <i>BMC Cancer</i> , <b>2007</b> , 7, 77	4.8	16
66	Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). <i>Chest</i> , <b>2007</b> , 132, 202S-220S	5.3	512
65	Endobronchial ultrasonography in bronchoscopic occult pulmonary lesions. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 121-4	8.9	42
64	Positron emission tomography in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2007</b> , 19, 78-83	4.2	12
63	Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3448-55	2.2	123
62	Positron emission tomography in nonsmall cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , <b>2007</b> , 13, 256-60	3	14
61	The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 603-12	8.9	415
60	The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1392-8	7.5	163
59	Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. <i>Cancer Treatment Reviews</i> , <b>2007</b> , 33, 461-73	14.4	103
58	Improving patient management in metastatic non-small cell lung cancer. <i>Lung Cancer</i> , <b>2007</b> , 57 Suppl 2, S12-7	5.9	14
57	Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 1347-55	3.5	3
56	Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.. <i>Blood</i> , <b>2007</b> , 110, 4086-4086	2.2	
55	PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemo-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S306	8.9	18
54	A1-07: Which patient is a candidate for surgery after induction treatment for stage IIIA-pN2 NSCLC? A prognostic stratification model based on morphometric-pathologic response in mediastinal nodes and primary tumour response on FDG-PET. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S311-S312	8.9	4
53	Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. <i>Journal of Clinical Oncology</i> , <b>2006</b> ,	2.2	180
52	Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 273-84	9.7	92

51	The Future in Diagnosis and Staging of Lung Cancer: Introduction. <i>Respiration</i> , <b>2006</b> , 73, 3-4	3.7	1
50	Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1057-63	2.2	252
49	The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 531-44	3.5	13
48	Staging of Lung Cancer. <i>PET Clinics</i> , <b>2006</b> , 1, 301-16	2.2	1
47	Second-line therapeutic options in non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2006</b> , 54 Suppl 2, S15-8	5.9	4
46	Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32 Suppl 2, S11-5	14.4	10
45	PET Scan in Lung Cancer: Current Recommendations and Innovation. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 71-73	8.9	12
44	Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia. <i>Therapeutics and Clinical Risk Management</i> , <b>2006</b> , 2, 175-86	2.9	4
43	PET Scan in Lung Cancer: Current Recommendations and Innovation. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 71-73	8.9	44
42	Staging procedures. <i>European Journal of Cancer, Supplement</i> , <b>2005</b> , 3, 7-19	1.6	2
41	Mediastinal emphysema and small cell lung cancer (SCLC): a case-report. <i>Lung Cancer</i> , <b>2005</b> , 47, 139-42	5.9	5
40	Early versus late chest radiotherapy for limited stage small cell lung cancer. <i>The Cochrane Library</i> , <b>2005</b> , CD004700	5.2	37
39	Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 263-9	4.3	26
38	Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6941-8	2.2	57
37	The future of adjuvant chemotherapy for resected non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 165-75	3.5	8
36	The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 429-40	4	6
35	Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8362-70	2.2	221
34	Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.. <i>Blood</i> , <b>2005</b> , 106, 3376-3376	2.2	7

33	Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2004</b> , 4, 5-17	3.5	37
32	Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 351-60	59.2	1781
31	The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. <i>Oncologist</i> , <b>2004</b> , 9, 633-43	5.7	171
30	Positron emission tomography in the management of non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 269-88	3.1	36
29	Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience. <i>Lung Cancer</i> , <b>2004</b> , 43, 39-45	5.9	43
28	Treatment of patients with advanced non-small cell lung cancer. <i>American Journal of Cancer</i> , <b>2004</b> , 3, 281-290		4
27	Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. <i>Respiratory Medicine</i> , <b>2004</b> , 98, 567-73	4.6	42
26	Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. <i>Lancet Oncology</i> , <b>2004</b> , 5, 531-40	21.7	181
25	Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. <i>Chest</i> , <b>2004</b> , 126, 1656-66	5.3	27
24	Hematopoietic Growth Factors in Lung Cancer <b>2004</b> , 249-274		
23	Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. <i>Expert Opinion on Biological Therapy</i> , <b>2003</b> , 3, 501-8	5.4	10
22	Pharmacotherapy of chemotherapy-induced anaemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2003</b> , 4, 2221-7		2
21	Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2003</b> , 4, 242-7	4.9	56
20	Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2237-46	2.2	2543
19	Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. <i>Lung Cancer</i> , <b>2003</b> , 40, 191-9	5.9	45
18	Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S3-6	5.9	9
17	PET scan in the staging of non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S27-37	5.9	32
16	Value of FDG-PET in the management of non-small cell lung cancer. <i>European Journal of Radiology</i> , <b>2003</b> , 45, 49-59	4.7	47

15	Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1211-20	9.7	390
14	Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 64, 33-6	5.3	
13	Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 1304-9	8.9	87
12	Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. <i>Lung Cancer</i> , <b>2001</b> , 31, 83-5	5.9	26
11	Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. <i>Lung Cancer</i> , <b>2001</b> , 34, 169-75	5.9	38
10	Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , <b>2000</b> , 11, 7-13	2.4	7
9	The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 55, 317-24	5.3	236
8	Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 55, 1-9	5.3	36
7	Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3201-6	2.2	375
6	Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. <i>European Journal of Cardio-thoracic Surgery</i> , <b>1999</b> , 15, 608-14	3	21
5	FDG-PET in the Locoregional Lymph Node Staging of Non-small Cell Lung Cancer. A Comprehensive Review of the Leuven Lung Cancer Group Experience. <i>Molecular Imaging and Biology</i> , <b>1999</b> , 2, 223-231		22
4	FDG-PET scan in potentially operable non-small cell lung cancer: do anatomometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1998</b> , 25, 1495-501	8.8	114
3	Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. <i>Lung Cancer</i> , <b>1998</b> , 19, 3-13	5.9	81
2	Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. <i>Chest</i> , <b>1997</b> , 112, 1480-6	5.3	143
1	Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. <i>Annals of Thoracic Surgery</i> , <b>1997</b> , 63, 1441-50	2.7	150